Share |
 Article not rated yet 

Amoxicillin, clavulanic acid and quinolones: is there something new?

Authors:

Ares Álvarez Ja, Martínez de la Ossa Sáenz-López Rb, Alfayate Miguélez Sc, Garrido Corro Bd, Grupo de Patología Infecciosa (GPI) e

aPediatra. CS Virgen Peregrina. Pontevedra. España .
bPediatra. CS El Parador. Roquetas de Mar, Almería. España.
cSección de Infectología Pediátrica. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia. España.
dServicio de Farmacia. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia. España.
eAsociación Española de Pediatría de Atención Primaria (AEPap).

Correspondence: J Ares. Email: finaares@gmail.com

Reference of this article.:

Ares Álvarez J, Martínez de la Ossa Sáenz-López R, Alfayate Miguélez S, Garrido Corro B, Grupo de Patología Infecciosa (GPI) . Amoxicilina, ácido clavulánico y quinolonas: ¿hay algo nuevo?. Rev Pediatr Aten Primaria. Supl. 2018;(27):33-44.

Published in Internet: 08/06/2018

Abstract:

Neither of these antimicrobials are innovations; both are widely spread therapeutic tools at primary health care. However, the interest for each of them is dramatically different from the pediatric point of view. On the one hand, the quinolones, overused in adults´ infectious patologies and restricted for children. On the other hand, the combination of amoxicillin with clanulanic acid, using different formulations, some of which has been almost forgotten and disdained by peditricians, is one of the most useful antibiotics in pediatrics. Old acquaintances, whose characteristics are worth updating. The selection of the right agent, along with the dose, the pattern and the duration will be essential both for an adequate treatment and to avoid bacterial resistences, and also to know their restrictions and possible adverse effects. Therefore, to deepen in the knowledge of these drugs will boost one of the elements of the fight against the increase of microbial resistances. The final goal will be to encourage the use of this antimicrobials, following the indications of guidelines and actual consensus.

Keywords: Off-label use. Quinolones. Drug compounding. Antimicrobials/adverse effects. Amoxicilin. Clavulanic acid.


 


Comments

This article has no comments yet.

ISSN 2174-4106  Publicación Open Acess, incluida en DOAJ, sin cargo por publicación.

Privacy Policy | Web map | Copyright 2022 Lúa Ediciones 3.0 | Contact